Quarterly ResultMay 5, 2026, 07:08 AM
Orthofix Q1 Net Sales $196.7M; Net Loss $(20.9)M; Reaffirms FY26 Guidance
AI Summary
Orthofix Medical Inc. reported first-quarter 2026 net sales of $196.7 million, a 1.6% increase year-over-year, and a net loss of $(20.9) million, significantly improved from $(53.1) million in the prior year. Non-GAAP pro forma net sales, excluding M6 product lines, grew 3% on a constant currency basis to $196.4 million. The company reaffirmed its full-year 2026 financial guidance, expecting net sales between $850 million and $860 million and non-GAAP adjusted EBITDA of $95 million to $98 million.
Key Highlights
- Q1 2026 reported net sales increased 1.6% to $196.7 million.
- Non-GAAP pro forma net sales grew 3% constant currency to $196.4 million.
- Reported net loss improved to $(20.9) million from $(53.1) million YoY.
- Non-GAAP pro forma adjusted EBITDA was $9.7 million.
- Global Spine Fixation net sales grew 6% reported and constant currency.
- Therapeutic Solutions net sales increased 5% year-over-year.
- Global Limb Reconstruction net sales grew 10% reported.
- Reaffirmed FY26 net sales guidance of $850M-$860M.